{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:13:27Z","timestamp":1756858407820,"version":"3.44.0"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Older adults with advanced prostate cancer and type 2 diabetes mellitus are underrepresented in trials of androgen receptor pathway inhibitors. This study examined changes in unplanned hospitalization rates in patients receiving androgen receptor pathway inhibitors by type 2 diabetes mellitus status and assessed if unplanned hospitalization varies according to androgen receptor pathway inhibitors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This population-based study of advanced prostate cancer patients aged older than 66 years used Surveillance, Epidemiology, and End Results\u2013Medicare data. Prepost androgen receptor pathway inhibitor initiation changes and androgen receptor pathway inhibitor differences in unplanned hospitalization rates were estimated by adjusted incidence rate ratio with considerations for interactions between period, androgen receptor pathway inhibitor, and type 2 diabetes mellitus status. Linear contrasts were used to estimate and test conditional incidence rate ratios. Tests were 2-sided, and a P\u2009value less than\u2009.05 was considered statistically significant.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study included 12\u2009240 patients: 3160 (25.8%) with type 2 diabetes mellitus, 7191 (58.8%) received abiraterone acetate with prednisone, and 5049 (41.2%) received enzalutamide. Unplanned hospitalization rates increased after androgen receptor pathway inhibitor initiation by 65% among patients with type 2 diabetes mellitus complications (adjusted incidence rate ratio = 1.65, 95% confidence interval [CI] = 1.37 to 1.98) and 109% in nondiabetics (adjusted incidence rate ratio = 2.09, 95% CI = 1.94 to 2.26). Among patients with type 2 diabetes mellitus without complications, the increase in unplanned hospitalization rates depended on the androgen receptor pathway inhibitor initiated: 103% after abiraterone acetate with prednisone (adjusted incidence rate ratio = 2.03, 95% CI = 1.70 to 2.43) and 47% after enzalutamide (adjusted incidence rate ratio = 1.47, 95% CI = 1.21 to 1.80) and a 38% greater increase in unplanned hospitalization rates after abiraterone acetate with prednisone than enzalutamide (ratio of abiraterone acetate with prednisone adjusted incidence rate ratio divided by enzalutamide adjusted incidence rate ratio = 1.38, 95% CI = 1.06 to 1.80).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>All patients had higher unplanned hospitalization rates after androgen receptor pathway inhibitor. Our findings highlight the importance of using real-world data to better understand the interplay between preexisting health conditions and treatment outcomes, a critical step toward precision medicine.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jncics\/pkaf070","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T14:12:57Z","timestamp":1752502377000},"source":"Crossref","is-referenced-by-count":0,"title":["Unplanned hospitalization among advanced prostate cancer patients by diabetes status: a population-based study"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0263-8708","authenticated-orcid":false,"given":"Amy L","family":"Shaver","sequence":"first","affiliation":[{"name":"Division of Population Science, Department of Medical Oncology, Sidney Kimmel Medical College at Thomas Jefferson University , Philadelphia, PA,","place":["United States"]},{"name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University , Philadelphia, PA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7697-0403","authenticated-orcid":false,"given":"Krupa","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Bioinformatics, Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Medical College at Thomas Jefferson University , Philadelphia, PA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9428-1151","authenticated-orcid":false,"given":"Scott W","family":"Keith","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University , Philadelphia, PA,","place":["United States"]},{"name":"Division of Biostatistics and Bioinformatics, Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Medical College at Thomas Jefferson University , Philadelphia, PA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6672-9772","authenticated-orcid":false,"given":"Nikita","family":"Nikita","sequence":"additional","affiliation":[{"name":"Division of Population Science, Department of Medical Oncology, Sidney Kimmel Medical College at Thomas Jefferson University , Philadelphia, PA,","place":["United States"]},{"name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University , Philadelphia, PA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5463-6926","authenticated-orcid":false,"given":"Christopher C","family":"Yang","sequence":"additional","affiliation":[{"name":"College of Computing and Informatics, Drexel University , Philadelphia, PA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6442-9223","authenticated-orcid":false,"given":"Felix J","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Medical College at Thomas Jefferson University , Philadelphia, PA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hushan","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Population Science, Department of Medical Oncology, Sidney Kimmel Medical College at Thomas Jefferson University , Philadelphia, PA,","place":["United States"]},{"name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University , Philadelphia, PA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William Kevin","family":"Kelly","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University , Philadelphia, PA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8104-6419","authenticated-orcid":false,"given":"Stephen J","family":"Freedland","sequence":"additional","affiliation":[{"name":"Department of Urology, Cedars-Sinai Medical Center , Los Angeles, CA,","place":["United States"]},{"name":"Section of Urology, Durham VA Medical Center , Durham, NC,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2925-7737","authenticated-orcid":false,"given":"Grace","family":"Lu-Yao","sequence":"additional","affiliation":[{"name":"Division of Population Science, Department of Medical Oncology, Sidney Kimmel Medical College at Thomas Jefferson University , Philadelphia, PA,","place":["United States"]},{"name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University , Philadelphia, PA,","place":["United States"]},{"name":"Jefferson College of Population Health, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"2025090216115137800_pkaf070-B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025090216115137800_pkaf070-B2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"2025090216115137800_pkaf070-B3","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.trecan.2020.12.010","article-title":"How comorbidities shape cancer biology and survival","volume":"7","author":"Panigrahi","year":"2021","journal-title":"Trends Cancer"},{"key":"2025090216115137800_pkaf070-B4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12885-019-6472-9","article-title":"Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers","volume":"20","author":"Fowler","year":"2020","journal-title":"BMC Cancer"},{"key":"2025090216115137800_pkaf070-B5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1089\/pop.2012.0028","article-title":"Effects of cancer comorbidity on disease management: Making the case for diabetes education (a report from the SOAR program)","volume":"16","author":"Irizarry","year":"2013","journal-title":"Popul Health Manag"},{"key":"2025090216115137800_pkaf070-B6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jgo.2015.12.002","article-title":"Comorbidity in older adults with cancer","volume":"7","author":"Williams","year":"2016","journal-title":"J Geriatr Oncol"},{"key":"2025090216115137800_pkaf070-B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071808","article-title":"Higher incidence of diabetes in cancer patients compared to cancer-free population controls: a systematic review and meta-analysis","volume":"14","author":"Yang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025090216115137800_pkaf070-B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194951","article-title":"Treatment pattern and outcomes with systemic therapy in men with metastatic prostate cancer in the real-world patients in the United States","volume":"13","author":"Swami","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025090216115137800_pkaf070-B9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1053\/j.seminoncol.2018.10.001","article-title":"Current therapeutic options in metastatic castration-resistant prostate cancer","volume":"45","author":"Ingrosso","year":"2018","journal-title":"Semin Oncol"},{"key":"2025090216115137800_pkaf070-B10","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.clgc.2021.07.009","article-title":"Beyond frontline therapy with abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: a real-world US study","volume":"19","author":"Shore","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"2025090216115137800_pkaf070-B11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.urology.2020.11.080","article-title":"A population-based study comparing outcomes for patients with metastatic castrate resistant prostate cancer treated by urologists or medical oncologists with first line abiraterone acetate or enzalutamide","volume":"153","author":"Woon","year":"2021","journal-title":"Urology"},{"key":"2025090216115137800_pkaf070-B12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1177\/1758834017698644","article-title":"Abiraterone acetate and prednisone in chemotherapy-na\u00efve prostate cancer patients: rationale, evidence and clinical utility","volume":"9","author":"Crawford","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"2025090216115137800_pkaf070-B13","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1634\/theoncologist.2014-0167","article-title":"Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer","volume":"19","author":"Auchus","year":"2014","journal-title":"Oncologist"},{"key":"2025090216115137800_pkaf070-B14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4103\/1008-682x.178483","article-title":"Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review","volume":"19","author":"Zhang","year":"2017","journal-title":"Asian J Androl"},{"key":"2025090216115137800_pkaf070-B15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.17925\/eoh.2013.09.1.34","article-title":"Modern management of castration-resistant prostate cancer","volume":"09","author":"Heidenreich","year":"2013","journal-title":"Eur Oncol Haematol"},{"key":"2025090216115137800_pkaf070-B16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/1756287213490054","article-title":"Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer","volume":"5","author":"Saad","year":"2013","journal-title":"Ther Adv Urol"},{"year":"2011","key":"2025090216115137800_pkaf070-B17"},{"year":"2012","key":"2025090216115137800_pkaf070-B18"},{"key":"2025090216115137800_pkaf070-B19","doi-asserted-by":"publisher","first-page":"7385","DOI":"10.1038\/s41598-021-86911-x","article-title":"Hospitalization rates for complications due to systemic therapy in the United States","volume":"11","author":"Saxena","year":"2021","journal-title":"Sci Rep"},{"key":"2025090216115137800_pkaf070-B20","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1377\/hlthaff.2014.0280","article-title":"Acute hospital care is the chief driver of regional spending variation in Medicare patients with advanced cancer","volume":"33","author":"Brooks","year":"2014","journal-title":"Health Affairs"},{"key":"2025090216115137800_pkaf070-B21","doi-asserted-by":"publisher","first-page":"e172450","DOI":"10.1001\/jamaoncol.2017.2450","article-title":"Trends in adult cancer-related emergency department utilization: an analysis of data from the nationwide emergency department sample","volume":"3","author":"Rivera","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025090216115137800_pkaf070-B22","doi-asserted-by":"publisher","first-page":"e2250423","DOI":"10.1001\/jamanetworkopen.2022.50423","article-title":"Trends and characteristics of potentially preventable emergency department visits among patients with cancer in the US","volume":"6","author":"Alishahi Tabriz","year":"2023","journal-title":"JAMA Network Open"},{"key":"2025090216115137800_pkaf070-B23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.annonc.2023.04.516","article-title":"Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study","volume":"34","author":"Curigliano","year":"2023","journal-title":"Ann Oncol"},{"key":"2025090216115137800_pkaf070-B24","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.clgc.2016.08.020","article-title":"Prostate cancer patients with unmanaged diabetes or receiving insulin experience inferior outcomes and toxicities after treatment with radiation therapy","volume":"15","author":"Zaorsky","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"2025090216115137800_pkaf070-B25","doi-asserted-by":"publisher","first-page":"9128","DOI":"10.1002\/cam4.5651","article-title":"Metformin use and hospital attendance-related resources utilization among diabetic patients with prostate cancer on androgen deprivation therapy: A population-based cohort study","volume":"12","author":"Lee","year":"2023","journal-title":"Cancer Medicine"},{"key":"2025090216115137800_pkaf070-B26","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41391-022-00588-5","article-title":"Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases","volume":"26","author":"Schoen","year":"2023","journal-title":"Prostate Cancer Prostat Dis"},{"key":"2025090216115137800_pkaf070-B27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"year":"2024","author":"NIH NCI","key":"2025090216115137800_pkaf070-B28"},{"key":"2025090216115137800_pkaf070-B29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/jncimonographs\/lgz029","article-title":"Updated overview of the SEER-Medicare data: enhanced content and applications","volume":"2020","author":"Enewold","year":"2020","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2025090216115137800_pkaf070-B30","first-page":"49","article-title":"What Medicare has meant to older Americans","volume":"18","author":"Moon","year":"1996","journal-title":"Health Care Financ Rev"},{"author":"Healthcare Delivery Research Program","key":"2025090216115137800_pkaf070-B31"},{"key":"2025090216115137800_pkaf070-B32","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.2522\/ptj.20080020","article-title":"Epidemiology of diabetes and diabetes-related complications","volume":"88","author":"Deshpande","year":"2008","journal-title":"Phys Ther"},{"key":"2025090216115137800_pkaf070-B33","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4239\/wjd.v11.i6.227","article-title":"Diabetes and cancer: epidemiological and biological links","volume":"11","author":"Wang","year":"2020","journal-title":"World J Diabetes"},{"key":"2025090216115137800_pkaf070-B34","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/pedi.12152","article-title":"Use of administrative and electronic health record data for development of automated algorithms for childhood diabetes case ascertainment and type classification: The SEARCH for Diabetes in Youth Study","volume":"15","author":"Zhong","year":"2014","journal-title":"Pediatr Diabetes"},{"key":"2025090216115137800_pkaf070-B35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2337\/dc21-2151","article-title":"Medical costs associated with diabetes complications in medicare beneficiaries aged 65 years or older with type 2 diabetes","volume":"46","author":"Wang","year":"2023","journal-title":"Diabetes Care"},{"volume-title":"How to Identify Emergency Room Services in the Medicare Claims Data","year":"2023","author":"Barosso","key":"2025090216115137800_pkaf070-B36"},{"key":"2025090216115137800_pkaf070-B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/303728","article-title":"Generalized estimating equations in longitudinal data analysis: a review and recent developments","volume":"2014","author":"Wang","year":"2014","journal-title":"Adv Stat"},{"key":"2025090216115137800_pkaf070-B38","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2307\/2531248","article-title":"Longitudinal data analysis for discrete and continuous outcomes","volume":"42","author":"Zeger","year":"1986","journal-title":"Biometrics"},{"key":"2025090216115137800_pkaf070-B39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.2023.41.6_suppl.75","article-title":"Survival and hemoglobin A1c in metastatic castrate resistant prostate cancer","volume":"41","author":"Govindan","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025090216115137800_pkaf070-B40","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1200\/jop.18.00254","article-title":"Unplanned hospitalization among individuals with cancer in the year after diagnosis","volume":"15","author":"Whitney","year":"2019","journal-title":"J Oncol Pract"},{"key":"2025090216115137800_pkaf070-B41","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.1111\/1475-6773.13001","article-title":"Planned and unplanned hospital admissions and their relationship with social factors: findings from a national, prospective study of people aged 76 years or older","volume":"53","author":"Dahlberg","year":"2018","journal-title":"Health Serv Res"},{"key":"2025090216115137800_pkaf070-B42","doi-asserted-by":"publisher","first-page":"h2361","DOI":"10.1136\/bmj.h2361","article-title":"The role of intervening hospital admissions on trajectories of disability in the last year of life: prospective cohort study of older people","volume":"350","author":"Gill","year":"2015","journal-title":"BMJ"},{"key":"2025090216115137800_pkaf070-B43","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1200\/jop.2016.019588","article-title":"Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012","volume":"13","author":"Tai","year":"2017","journal-title":"J Oncol Pract"},{"key":"2025090216115137800_pkaf070-B44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/ncc.0000000000000360","article-title":"A systematic review of emergency department use among cancer patients","volume":"40","author":"Lash","year":"2017","journal-title":"Cancer Nurs"},{"key":"2025090216115137800_pkaf070-B45","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s44201-022-00005-6","article-title":"Cancer-related emergency and urgent care: expanding the research agenda","volume":"1","author":"Shelburne","year":"2022","journal-title":"Emerg Cancer Care"},{"year":"2018","author":"Abiraterone approved for earlier use in men with metastatic prostate cancer","key":"2025090216115137800_pkaf070-B46"},{"year":"2019","author":"FDA approves enzalutamide for metastatic castration-sensitive prostate cancer","key":"2025090216115137800_pkaf070-B47"},{"key":"2025090216115137800_pkaf070-B48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153773","article-title":"Outcomes following abiraterone versus enzalutamide for prostate cancer: a scoping review","volume":"14","author":"Shah","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025090216115137800_pkaf070-B49","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s12325-018-0774-1","article-title":"Treatment duration, healthcare resource utilization, and costs among chemotherapy-na\u00efve patients with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate: a retrospective claims analysis","volume":"35","author":"Schultz","year":"2018","journal-title":"Adv Ther"},{"key":"2025090216115137800_pkaf070-B50","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1007\/s12325-023-02572-4","article-title":"Healthcare costs in men with metastatic castration-resistant prostate cancer: an analysis of US Medicare fee-for-service claims","volume":"40","author":"Freedland","year":"2023","journal-title":"Adv Ther"},{"key":"2025090216115137800_pkaf070-B51","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.37765\/ajmc.2023.89429","article-title":"Characteristics of self-triaged emergency department visits by adults with cancer","volume":"29","author":"Hong","year":"2023","journal-title":"Am J Manag Care"},{"key":"2025090216115137800_pkaf070-B52","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/0284186X.2021.1885058","article-title":"Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden","volume":"60","author":"George","year":"2021","journal-title":"Acta Oncologica"},{"key":"2025090216115137800_pkaf070-B53","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.eururo.2019.07.031","article-title":"Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities","volume":"77","author":"Lu-Yao","year":"2020","journal-title":"Eur Urol"},{"key":"2025090216115137800_pkaf070-B54","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12872-021-01945-3","article-title":"Syncope due to non-sustained episodes of Torsade de Pointes associated to androgen-deprivation therapy use: a case presentation","volume":"21","author":"Morales","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"2025090216115137800_pkaf070-B55","doi-asserted-by":"publisher","first-page":"e2428444","DOI":"10.1001\/jamanetworkopen.2024.28444","article-title":"Abiraterone or enzalutamide for patients with metastatic castration-resistant prostate cancer","volume":"7","author":"La","year":"2024","journal-title":"JAMA Network Open"},{"key":"2025090216115137800_pkaf070-B56","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejca.2022.04.034","article-title":"Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: a randomised clinical trial (HEAT)","volume":"171","author":"Ternov","year":"2022","journal-title":"Eur J Cancer"},{"key":"2025090216115137800_pkaf070-B57","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","article-title":"The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer","volume":"16","author":"Iacovelli","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"2025090216115137800_pkaf070-B58","doi-asserted-by":"publisher","first-page":"e592","DOI":"10.1016\/j.clgc.2019.03.001","article-title":"Cardiovascular and metabolic toxicity of abiraterone in castration-resistant prostate cancer: post-marketing experience","volume":"17","author":"Tsao","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"2025090216115137800_pkaf070-B59","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.clgc.2023.07.006","article-title":"Hospitalizations among veterans treated for metastatic prostate cancer with abiraterone or enzalutamide","volume":"22","author":"Riekhof","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"2025090216115137800_pkaf070-B60","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3233\/jad-2009-1099","article-title":"The accuracy of Medicare claims as an epidemiological tool: the case of dementia revisited","volume":"17","author":"Taylor","year":"2009","journal-title":"J Alzheimers Dis"},{"key":"2025090216115137800_pkaf070-B61","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/15384047.2017.1394555","article-title":"Expanding the use of abiraterone in prostate cancer: Is earlier always better?","volume":"19","author":"Schmidt","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"2025090216115137800_pkaf070-B62","doi-asserted-by":"publisher","first-page":"100887","DOI":"10.1016\/j.eclinm.2021.100887","article-title":"Cardiovascular toxicities associated with abiraterone compared to enzalutamide-a pharmacovigilance study","volume":"36","author":"Cone","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2025090216115137800_pkaf070-B63","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jgo.2020.03.001","article-title":"Relationship between polypharmacy and inpatient hospitalization among older adults with cancer treated with intravenous chemotherapy","volume":"11","author":"Lu-Yao","year":"2020","journal-title":"J Geriatr Oncol"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkaf070\/63778976\/pkaf070.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/9\/5\/pkaf070\/63778976\/pkaf070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/9\/5\/pkaf070\/63778976\/pkaf070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T20:12:01Z","timestamp":1756843921000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkaf070\/8203481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkaf070","relation":{},"ISSN":["2515-5091"],"issn-type":[{"type":"electronic","value":"2515-5091"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,7,16]]},"article-number":"pkaf070"}}